Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2'-deoxyadenosine.
A few cases of secondary neoplasms occurring after treatment with 2-chloro-2'-deoxyadenosine (2CdA) have been reported, mostly in patients previously exposed to other anti-cancer drugs including alkylating agents (AA). Here we report on the occurrence of a myelodysplastic syndrome (MDS) with monosomy 5 and/or 7 in two patients after 2CdA treatment, without or prior to other toxic exposure. In light of a literature review and given the involvement of chromosomes frequently abnormal in secondary leukaemias, we suggest that 2CdA may induce therapy-related MDS (t-MDS).
Van Den Neste
E
E
Department of Haematology, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium. vandenneste@sang.ucl.ac.be
Louviaux
I
I
Michaux
J L
JL
Delannoy
A
A
Michaux
L
L
Hagemeijer
A
A
Scheiff
J M
JM
Bosly
A
A
Straetmans
N
N
Ferrant
A
A
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics*; D017338:Cladribine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009006:Monosomy / Q000235:genetics*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics*
D000970:Antineoplastic Agents; D017338:Cladribine